文献速递泌尿生殖技术与安全MR

英国前列腺多参数磁共振成像:全国现状调查

Prostate mpMRI in the UK: the state of the nation.
PubMed 文献 · Clin Radiol · 2019-01-01

本文通过2016年和2018年两次信息自由请求评估英国在活检前使用前列腺多参数磁共振成像(mpMRI)的现状与进展。结果显示活检前mpMRI使用率提高,59%的地区报告改善,未提供任何形式活检前MRI的地区从2016年的25%降至2018年的13%,但英国各组成部分之间及内部仍存在地理差异和实施障碍,包括扫描仪容量和人员配备不足。

要点

  • 活检前mpMRI使用率提高,59%的地区在两次请求之间报告改善。
  • 未提供任何形式活检前MRI的地区从2016年的25%降至2018年的13%。
  • 部分地区的mpMRI扫描不使用动态对比增强(DCE),并依据检查结果决定是否转诊活检。

核心结论

  • 英国活检前mpMRI的使用率在2016年至2018年间有所提高,59%的地区报告改善;未提供任何形式活检前MRI的地区从25%降至13%;但英国各组成部分之间仍存在地理差异,实施障碍包括扫描仪容量和人员配备水平。

研究设计与样本

  • 研究通过英国前列腺癌协会(PCUK)和英国泌尿生殖放射学会于2016年向英国各卫生区域提交信息自由(FOI)请求,以及PCUK于2018年再次提交请求,评估活检前mpMRI作为初始诊断路径一部分的使用情况,并识别实施障碍。

临床应用与阅片要点

  • 文章指出,近期英国国家卫生与临床优化研究所(NICE)和英格兰国民医疗服务体系(NHS England)的指南和建议提出,50-69岁且前列腺特异性抗原(PSA)水平在>3至<30 ng/ml之间的男性应在活检前接受mpMRI,这给本已人手不足和资源匮乏的放射科带来了进一步压力。

局限性

  • 原文指出英国各组成部分之间在实施上仍存在地理差异。
  • 原文指出影像实践存在差异,一些地区进行扫描时不使用动态对比增强(DCE),并利用检查结果指导活检转诊决策。
  • 原文指出活检前MRI的入选标准也存在差异,导致一些限制性做法。
  • 原文报告的实施的障碍包括扫描仪容量和人员配备水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The diagnosis of prostate cancer has changed. Improved magnetic resonance imaging (MRI) technology with diffusion-weighted imaging has led to the use of multiparametric MRI (mpMRI) before biopsy in patients suspected of having prostate cancer. This has the advantage that patients with a negative mpMRI may not need biopsy, therefore avoiding the risk of complications. Those in whom mpMRI is positive can have targeted biopsies with a higher probability of diagnosing clinically significant cancer. Prostate Cancer UK (PCUK) and the British Society of Urogenital Radiology submitted a Freedom of Information (FOI) request in 2016 to UK health areas in order to assess the use of mpMRI before biopsy as part of the initial diagnosis pathway. Another request was submitted by PCUK in 2018 to assess the progress made in the UK between these two dates. Both requests had the secondary aim of identifying barriers to the implementation of mpMRI. The FOI requests showed an increase in the use of mpMRI before biopsy with 59% of areas reporting improvement between the two requests. There has been a reduction in the percentage of areas not providing any form of pre-biopsy MRI from 25% in 2016 to 13% in 2018. There remains, however, geographical variation in implementation across the UK nations. Imaging practice also shows variation with some areas performing scans without dynamic contrast enhancement (DCE) and using the findings to guide referral decisions for biopsy. Eligibility criteria for pre-biopsy MRI also vary leading to some restrictive practices. Reported barriers to implementation included scanner capacity and staffing levels. Recent guidelines and recommendations by the National Institute for Health and Care Excellence (NICE) and NHS England for men aged 50-69 years with a prostate-specific antigen (PSA) level between >3 and <30 ng/ml to receive mpMRI before biopsy put further pressure on already understaffed and under-resourced radiology departments.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Davies C, Castle JT, Stalbow K, et al. Prostate mpMRI in the UK: the state of the nation. Clin Radiol. 2019. PMID: 31627803. doi:10.1016/j.crad.2019.09.129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。